Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of avelumab + cetuximab + modified FOLFOXIRI as initial therapy for RAS wild-type unresectable metastatic colorectal cancer
2019-001501-24Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab, cetuximab, fluorouracil, oxaliplatin, irinotecan and 1 more in metastatic colorectal adenocarcinoma (mCRC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
avelumabcetuximabfluorouraciloxaliplatinirinotecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2019-001501-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001501-24.